Boston Scientific Corporation (BSX) recently reported that the first U.S. procedures performed with its all-in-one Symphion System, devised for the purpose of hysteroscopic removal of interuterine fibroids and polyps, have been successfully completed.
The Symphion System incorporates breakthrough technologies that jointly work toward efficient uterine tissue removal with greater patient safety.
Boston Scientific plans to launch the Symphion System at the American Association of Gynecologic Laparoscopists (AAGL) 43rd Global Congress to be held in Vancouver, British Columbia, from Nov 17 to 20.
In May 2014, Boston Scientific acquired IoGyn, Inc. – a pre-commercial stage company and the original developer of the next generation Symphion System. This acquisition opened up scope for pairing the FDA-cleared Symphion System with Boston Scientific's Genesys HTA System that is used to treat abnormal uterine bleeding. Together, the two devices have created a compelling set of cost-effective gynecologic surgery solution.
At present, about 2 million women in the U.S. are estimated to be affected by uterine fibroids and polyps every year. Of these, roughly 25% cases result in further deterioration of women's health.
In the last reported quarter – third quarter of 2014 – Boston Scientific's Urology and Women's Health segment outperformed the market. The company is focused on its current strategy to constantly invest in key international geographies. This naturally resulted in double-digit growth in all international regions of this segment for the fifth consecutive quarter.
While management believes that the successful completion of the first surgical procedures in the U.S. validates the robust potential of this system, we believe this achievement will aid revenue numbers for Boston Scientific's Women's Health segment in the coming quarters.
Moreover, once Boston Scientific makes the Symphion System available in the international market, we believe it will experience enormous demand therein, particularly in the populous emerging markets, where a large number of women generally suffer from gynecological problems.
Zacks Rank
Currently, Boston Scientific holds a Zacks Rank #2 (Buy). Some other stocks which warrant a look in the medical products industry include GW Pharmaceuticals plc (GWPH), ICU Medical, Inc. (ICUI) and OraSure Technologies, Inc. (OSUR). All three stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment